AZTAAzenta, Inc.
Price
+21%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, demanding price, growth steady, the market undecided.
We are a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. We entered the life sciences market in 2011, leveraging our in-house precision automation and cryogenics capabilities that we were then applying in the semiconductor manufacturing market. This led us to develop and provide solutions for automated ultra-cold storage. Since then, we have expanded our life sciences offerings through internal investments and through a series of acquisitions.
In the company’s own words · 10-K filed Dec 4, 2025 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Azenta, Inc. (AZTA) reported revenue of $161M in Q3 2026 (quarter ended Jun 30, 2026), up 12% from the same quarter a year earlier. That came with a gross margin of 45% and net income of $2.5M (1.5% of revenue). For the full year FY2025, revenue was $594M (+3.6% year on year) and net income −$56M. Its largest region in Q3 2026 was United States at $92M, 57% of the disclosed total, well ahead of Europe at 19%. The next results filing is expected around Nov 20, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 7, 2026On October 5, 2026, the Board of Directors of Azenta, Inc. (the “Company”) approved, and the Company committed to, a restructuring plan (the “Plan”) within the Company’s Multiomics reportable segment.Exit or disposal costs (restructuring) · Form 8-K
- Sep 17, 2026Interim President and Chief Executive Officer Compensation As previously disclosed in the Company’s Current Report on Form 8-K filed on August 24, 2026, the Board of Directors (the “Board”) of Azenta, Inc. (the “Company”) appointed Dr. Martin D. Madaus as the Company’s Interim President and Chief Executive Officer …Director or officer change · Form 8-K
- Sep 4, 2026As previously disclosed in the Company’s Current Report on Form 8-K filed on July 8, 2026, on July 1, 2026, in connection with the completion of the sale by Azenta Germany GmbH, a wholly owned subsidiary of the Company, of the entire issued share capital of B Medical Systems S.à r.l.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $161.2MThe company’s own SEC segment disclosure.
- United States$91.5M57%
- Europe$30.0M19%
- China$18.8M12%
- United Kingdom$12.1M8%
- Asia Pacific Excluding China$6.9M4%
- Other$1.9M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #15 of 21 by RyuScore